Prelude Therapeutics (PRLD) Competitors $0.91 -0.07 (-6.91%) Closing price 04:00 PM EasternExtended Trading$0.89 -0.02 (-2.31%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. FDMT, ENGN, PBYI, KRRO, LFVN, SLS, FTLF, NKTX, CYBN, and TNGXShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include 4D Molecular Therapeutics (FDMT), enGene (ENGN), Puma Biotechnology (PBYI), Korro Bio (KRRO), LifeVantage (LFVN), SELLAS Life Sciences Group (SLS), FitLife Brands (FTLF), Nkarta (NKTX), Cybin (CYBN), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. 4D Molecular Therapeutics enGene Puma Biotechnology Korro Bio LifeVantage SELLAS Life Sciences Group FitLife Brands Nkarta Cybin Tango Therapeutics 4D Molecular Therapeutics (NASDAQ:FDMT) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Does the MarketBeat Community favor FDMT or PRLD? 4D Molecular Therapeutics received 26 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 65.56% of users gave 4D Molecular Therapeutics an outperform vote while only 51.56% of users gave Prelude Therapeutics an outperform vote. CompanyUnderperformOutperform4D Molecular TherapeuticsOutperform Votes5965.56% Underperform Votes3134.44% Prelude TherapeuticsOutperform Votes3351.56% Underperform Votes3148.44% Do insiders and institutionals hold more shares of FDMT or PRLD? 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 63.9% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, FDMT or PRLD? 4D Molecular Therapeutics has higher earnings, but lower revenue than Prelude Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$23K7,754.40-$100.84M-$3.18-1.21Prelude Therapeutics$7M7.92-$121.83M-$1.69-0.58 Do analysts rate FDMT or PRLD? 4D Molecular Therapeutics currently has a consensus price target of $29.56, suggesting a potential upside of 667.68%. Prelude Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 307.33%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer FDMT or PRLD? In the previous week, 4D Molecular Therapeutics had 15 more articles in the media than Prelude Therapeutics. MarketBeat recorded 15 mentions for 4D Molecular Therapeutics and 0 mentions for Prelude Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.67 beat Prelude Therapeutics' score of 0.15 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Overall Sentiment 4D Molecular Therapeutics Positive Prelude Therapeutics Neutral Which has more risk and volatility, FDMT or PRLD? 4D Molecular Therapeutics has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Is FDMT or PRLD more profitable? 4D Molecular Therapeutics' return on equity of -28.00% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular TherapeuticsN/A -28.00% -26.16% Prelude Therapeutics N/A -66.89%-55.59% Summary4D Molecular Therapeutics beats Prelude Therapeutics on 13 of the 17 factors compared between the two stocks. Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.44M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.559.1426.7920.05Price / Sales7.92255.59395.67116.44Price / CashN/A65.8538.2534.62Price / Book0.236.546.864.61Net Income-$121.83M$143.51M$3.22B$248.19M7 Day Performance8.76%5.60%6.80%2.97%1 Month Performance22.95%10.06%13.69%16.58%1 Year Performance-75.99%-0.86%18.25%8.16% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics3.085 of 5 stars$0.91-6.9%$4.00+337.6%-76.2%$51.61M$7M-0.51120FDMT4D Molecular Therapeutics2.9138 of 5 stars$3.32+7.8%$29.56+790.2%-85.2%$153.80M$37,000.00-1.16120Gap UpENGNenGene2.8781 of 5 stars$2.97+0.3%$23.29+684.0%-66.9%$151.40MN/A-5.1231Positive NewsPBYIPuma Biotechnology3.5583 of 5 stars$3.04+4.5%$7.00+130.3%-16.9%$150.88M$230.47M6.33200KRROKorro Bio2.0106 of 5 stars$15.98+2.7%$112.75+605.6%-70.4%$150.07M$2.27M-1.6970Analyst RevisionGap UpLFVNLifeVantage3.9893 of 5 stars$11.86-3.3%$30.50+157.2%+84.5%$149.29M$222.35M21.18260Positive NewsSLSSELLAS Life Sciences Group0.3128 of 5 stars$1.54-1.3%N/A+31.1%$145.60M$1M-2.2310Gap UpFTLFFitLife Brands4.4454 of 5 stars$15.41-1.9%$20.50+33.0%+0.9%$144.61M$64.47M18.2420Earnings ReportNKTXNkarta1.9798 of 5 stars$2.02+4.7%$14.83+634.3%-73.3%$143.34MN/A-1.07140Trending NewsEarnings ReportAnalyst RevisionGap UpCYBNCybin2.7493 of 5 stars$6.62-6.1%$86.00+1,199.1%N/A$142.18MN/A-1.5150News CoverageTNGXTango Therapeutics1.5872 of 5 stars$1.31+14.9%$12.33+841.5%-73.0%$141.62M$42.07M-1.1190 Related Companies and Tools Related Companies 4D Molecular Therapeutics Alternatives enGene Alternatives Puma Biotechnology Alternatives Korro Bio Alternatives LifeVantage Alternatives SELLAS Life Sciences Group Alternatives FitLife Brands Alternatives Nkarta Alternatives Cybin Alternatives Tango Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRLD Stock Free PRLD Stock Alerts